🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Tilray's Deal To Buy Hemp Food Maker Bolsters Marijuana ETF

Published 02/20/2019, 10:25 PM
Updated 07/09/2023, 06:31 AM
WEED
-
TLAA
-
ACB
-
TLRY
-

The easing of rules and regulations on the once highly guarded drug, marijuana, for recreational and medical usage has led to consolidation in the pot industry, which is buzzing hot with a wave of mergers, acquisitions and other deals. The latest catalyst is Canadian cannabis firm Tilray Inc. (NASDAQ:TLRY) , which has announced a deal to acquire the world’s largest hemp food maker Manitoba Harvest for up to C$419 million ($318 million).

Inside The Deal

Tilray will initially pay C$277.5 million (C$150 million in cash and C$127.5 million in Tilray shares) at the close of the deal, expected within the next 30 days. The remainder will be paid six months after closure and achievement of certain milestones.

The combined company will bring nutritious hemp foods and supplements to more households across the United States and Canada. The acquisition will expand Tilray’s product portfolio into the natural foods category and bring Manitoba Harvest expertise in working with cannabinoids, including cannabidiol (CBD). It gives Tilray an immediate position in the North American hemp CBD market. As such, Tilray expects to launch CBD-derived products in the United States as early as this summer (read: Why Marijuana ETFs are on a High in 2019).

The planned acquisition comes within a few months of Trump’s farm bill, which legalized commercial production of hemp in the country and opened access to a large market for Tilray and its peers.

Big Opportunity in CBD Market

With this deal, Tilray appears to be leapfrogging its biggest rivals — Aurora Cannabis (TO:ACB) and Canopy Growth (NYSE:CGC) — in capitalizing the rapidly expanding U.S. CBD market. Canopy Growth is the first company to tap on the CBD market by announcing that it had secured a license to produce and process hemp in New York state. Canopy Growth expects to market hemp-based CBD products by the end of 2019 in U.S. states where they are allowed. Meanwhile, Aurora Cannabis is in the process of acquiring hemp assets (read: Forget Mixed Pot Earnings; Bet on ETF on Growth Prospects).

Some analysts estimate that the U.S. CBD market could be worth more than $20 billion by 2022, up from the current $600 million. The Hemp Business Journal projects that the market will grow to $1.3 billion by 2022, reflecting an impressive compound annual growth rate (CAGR) of more than 27%. Per Cannabis market researcher Brightfield Group, the U.S. hemp CBD market will soar to $22 billion by 2022.

ETF Impact

The announced deal has bolstered the outlook of the already high-flying ETFMG Alternative Harvest ETF (SNX:MJ) . It is the first and only pure ETF targeting the cannabis/marijuana industry.

The fund tracks the Prime Alternative Harvest Index, designed to measure the performance of companies within the cannabis ecosystem, benefiting from global medicinal and recreational cannabis legalization initiatives. The fund holds 38 securities in its basket with each accounting for no more than 8.21% of assets.

Canadian firms make up 61.9% of the portfolio, while American firms comprise 24.2%. With AUM of more than $1 billion, the ETF trades in a solid average daily volume of around million shares and charges 75 bps in annual fees. It has soared 45.3% so far this year (read: Marijuana ETF Joins Billion Dollar Club).

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>



Tilray, Inc. (TLRY): Free Stock Analysis Report

Canopy Growth Corporation (CGC): Free Stock Analysis Report

Aurora Cannabis Inc. (ACB): Get Free Report

ETFMG Alternative Harvest ETF (MJ): ETF Research Reports

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.